Skip to main content
. Author manuscript; available in PMC: 2020 Aug 4.
Published in final edited form as: Metabolism. 2019 Feb 23;94:69–76. doi: 10.1016/j.metabol.2019.01.007

Table 5.

Hazard ratios (HR) and 95% confidence intervals (CI) for cancer mortality by inflammatory and metabolic biomarkers by race

BMI categories
Normal BMI (18.5 ≤ BMI <25 kg/m2) Ove rweight or Obese (BMI ≥25 kg/m2) pint with BMI
Log-Transformed§ Log Transformed§
Black Participants (N=798, cancer death=40)
IL-6
 Model 1 3.6(1.2, 10.6)* 3.4 (1.6, 7.0)** 0.008
 Model 2 4.7 (1.3, 16.9)* 3.3 (1.6, 7.0)* 0.021
 Model 3 5.9 (1.5, 23.1)* 3.0 (1.3, 6.9)* 0.156
CRP
 Model 1 1.4 (0.9, 2.0) 1.3 (0.9, 2.0) 0.039
 Model 2 1.4 (0.9, 1.9) 1.3 (0.9, 2.0) 0.043
 Model 3 1.3 (0.7, 2.2) 1.3 (0.9, 2.0) 0.396
Resistin
 Model 1 4.4 (0.6, 31.4) 1.3 (0.7, 2.3) 0.007
 Model 2 4.2 (0.7, 26.9) 1.3 (0.7, 2.3) 0.013
 Model 3 8.5 (2.0, 35.8)** 1.3 (0.7, 2.5) 0.008
White Participants (N=1024, cancer death=46)
IL-6
 Model 1 2.6 (0.8, 9.1) 2.4 (1.0, 5.7)* 0.269
 Model 2 3.0 (0.8, 12.0) 3.1 (1.3, 7.5)* 0.278
 Model 3 1.0 (0.20, 4.6) 2.7 (1.1, 6.4)* 0.649
CRP
 Model 1 1.8(1.1, 3.1)* 0.9 (0.6, 1.3) 0.115
 Model 2 1.9 (1.0, 3.4)* 0.9 (0.6, 1.4) 0.131
 Model 3 1.7 (1.2, 2.5)** 1.0 (0.6, 1.5) 0.571
Resistin
 Model 1 1.3 (0.3, 5.5) 0.4 (0.1, 1.6) 0.625
 Model 2 1.3 (0.3, 6.0) 0.4 (0.1, 1.8) 0.454
 Model 3 3.6 (0.5, 24.2) 0.4 (0.1, 2.5) <0.0001

Crude model included the exposure and age.

Model 1 adjusted for age, gender, education, and income

Model 2 additionally adjusted for exercise

Model 3 further adjusted for comorbidity scores, smoking, alcohol, aspirin, and statin use

§

Biomarkers (except CRP) were log-transformed due to non-normal distributions

Bold indicates significance at 0.05 alpha level.

**

p-values were ≤0.01;

*

p-values were ≤0.05 while the rest of p-values were >0.05.

pint, p for the interaction of the log form with BMI. The p-values are from type 3 tests.P for the interaction is considered significant at alpha=0.1